Reason for request

Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals


Clinical Benefit


The actual benefit of DIACOMIT is substantial.

Clinical Added Value


DIACOMIT provides a moderate (level III) improvement in actual benefit in the management of patients with severe myoclonic epilepsy in infancy when the sodium valproate-clobazam combination does not provide adequate control.

Contact Us

Évaluation des médicaments
All our publications